PMID- 36497437
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 23
DP  - 2022 Dec 1
TI  - Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
LID - 10.3390/cancers14235955 [doi]
LID - 5955
AB  - BACKGROUND: Cervical cancer (CC) constitutes the fourth most common tumor among 
      the female population. Therapeutic approaches to advanced CC are limited, with 
      dismal results in terms of survival, mainly after progression to platinum-based 
      regimens. Immune checkpoint inhibitors (ICIs) are remodeling the therapeutic 
      scenario of many solid tumors. The role of ICIs in CC should be addressed. 
      Therefore, we systematically reviewed the latest clinical trials employing ICIs 
      in advanced CC to assess which ICIs have been employed and how ICIs might meet 
      the need for new therapeutic options in terms of efficacy and safety. METHODS: 
      The review was conducted following the PRISMA guidelines. The following efficacy 
      outcomes were specifically collected: overall response rate (ORR), disease 
      control rate (DCR), progression-free survival (PFS), and overall survival (OS); 
      for safety: type, number, and grade of adverse events (AEs). RESULTS: A total of 
      17 studies were analyzed. Anti-PD1 (pembrolizumab, nivolumab, cemiplimab, 
      balstilimab, and tislelizumab), anti-PD-L1 (atezolizumab), and anti-CTLA-4 
      (ipilimumab, zalifrelimab) agents were employed both as single agents or 
      combinations. Overall ORR ranged from 0% to 65.9%. ORR ranged from 5.9% to 69.6% 
      in PD-L1-positive patients and from 0% to 50% in PD-L1-negative patients. DCR was 
      30.6-94.1%. mPFS ranged from 2 to 10.4 months. mOS ranged from 8 months to not 
      reached. PD-L1 status did not impact survival. A total of 33.9% to 100% of 
      patients experienced AEs. CONCLUSION: Immunotherapy represents an appealing 
      strategy for patients with advanced CC, as 2 out of 3 patients seem to respond to 
      ICIs. PD-L1 status might be an indicator of response without impacting survival.
FAU - Maiorano, Brigida Anna
AU  - Maiorano BA
AUID- ORCID: 0000-0001-5423-3158
AD  - Oncology Unit, Fondazione Casa Sollievo della Sofferenza IRCCS, 71013 San 
      Giovanni Rotondo, Italy.
AD  - Department of Translational Medicine and Surgery, Catholic University of the 
      Sacred Heart, 00168 Rome, Italy.
FAU - Maiorano, Mauro Francesco Pio
AU  - Maiorano MFP
AUID- ORCID: 0000-0003-2621-0965
AD  - Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human 
      Oncology, University of Bari "Aldo Moro", 70121 Bari, Italy.
FAU - Ciardiello, Davide
AU  - Ciardiello D
AD  - Oncology Unit, Fondazione Casa Sollievo della Sofferenza IRCCS, 71013 San 
      Giovanni Rotondo, Italy.
AD  - Medical Oncology, Department of Precision Medicine, Luigi Vanvitelli University 
      of Campania, 80131 Naples, Italy.
FAU - Maglione, Annamaria
AU  - Maglione A
AD  - Obstetrics and Gynecology Department, Fondazione Casa Sollievo della Sofferenza 
      IRCCS, 71013 San Giovanni Rotondo, Italy.
FAU - Orditura, Michele
AU  - Orditura M
AD  - Medical Oncology, Department of Precision Medicine, Luigi Vanvitelli University 
      of Campania, 80131 Naples, Italy.
FAU - Lorusso, Domenica
AU  - Lorusso D
AD  - Department of Women and Child Health, Division of Gynaecologic Oncology, 
      Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
AD  - Scientific Directorate, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 
      00168 Rome, Italy.
FAU - Maiello, Evaristo
AU  - Maiello E
AUID- ORCID: 0000-0003-3890-3435
AD  - Oncology Unit, Fondazione Casa Sollievo della Sofferenza IRCCS, 71013 San 
      Giovanni Rotondo, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221201
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9737392
OTO - NOTNLM
OT  - HPV
OT  - ICI
OT  - PD-L1
OT  - cemiplimab
OT  - cervical cancer
OT  - checkpoint inhibitor
OT  - immunotherapy
OT  - ipilimumab
OT  - nivolumab
OT  - pembrolizumab
COIS- The authors do not report conflicts of interest regarding the preparation of this 
      manuscript.
EDAT- 2022/12/12 06:00
MHDA- 2022/12/12 06:01
PMCR- 2022/12/01
CRDT- 2022/12/11 01:05
PHST- 2022/09/21 00:00 [received]
PHST- 2022/11/27 00:00 [revised]
PHST- 2022/11/28 00:00 [accepted]
PHST- 2022/12/11 01:05 [entrez]
PHST- 2022/12/12 06:00 [pubmed]
PHST- 2022/12/12 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - cancers14235955 [pii]
AID - cancers-14-05955 [pii]
AID - 10.3390/cancers14235955 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Dec 1;14(23):5955. doi: 10.3390/cancers14235955.